Metabolism-Clinical and Experimental

Article	Citations
Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York	608
Obesity in patients with COVID-19: a systematic review and meta-analysis	323
Complications, morbidity and mortality of nonalcoholic fatty liver disease	272
A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on	271
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease	244
Insulin resistance, cardiovascular stiffening and cardiovascular disease	243
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses	242
MAFLD and risk of CKD	177
Commentary: Obesity: The “Achilles heel” for COVID-19?	158
Role of the gut microbiota in type 2 diabetes and related diseases	155
Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19	147
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease	139
The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany	138
The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis	134
Commentary: Testosterone, a key hormone in the context of COVID-19 pandemic	133
Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019	125
Commentary: COVID-19 in patients with diabetes	121
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk	105
Letter to the Editor: Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China	101
Metformin: Is it a drug for all reasons and diseases?	99
Visceral fat is associated to the severity of COVID-19	96
Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: A dose-response meta-analysis	95
The serum metabolome of COVID-19 patients is distinctive and predictive	92
Insulin resistance and insulin sensitizing agents	90
Metabolic liver disease in diabetes – From mechanisms to clinical trials	89

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis	89
Epidemiology of sarcopenia: Prevalence, risk factors, and consequences	88
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes	86
Heart failure in diabetes	85
Insulin: The master regulator of glucose metabolism	80
Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy	76
FUNDC1 insufficiency sensitizes high fat diet intake-induced cardiac remodeling and contractile anomaly through ACSL4-mediated ferroptosis	71
The effect of underweight on female and male reproduction	71
Letter to the Editor: COVID-19 in patients with diabetes: Risk factors that increase morbidity	70
The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease	67
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression	65
The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis	64
Mediterranean diet as a nutritional approach for COVID-19	62
Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis	62
Commentary: COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next	61
Diabetes and COVID-19: The past, the present, and the future	61
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?	59
Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data	59
Letter to the Editor: Vitamin D deficiency in COVID-19: Mixing up cause and consequence	59
Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?	58
Impact of body composition on COVID-19 susceptibility and severity: A two-sample multivariable Mendelian randomization study	58
Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies	56
Factors affecting weight loss variability in obesity	52
FOS/GOS attenuates high-fat diet induced bone loss via reversing microbiota dysbiosis, high intestinal permeability and systemic inflammation in mice	51
The effect of excess body fat on female and male reproduction	51
A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage	50
Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19	49
Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway	49
Myocardial ketone body utilization in patients with heart failure: The impact of oral ketone ester	48
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes	48
Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19	47
PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)	46
Effect of alternate-day fasting on obesity and cardiometabolic risk: A systematic review and meta-analysis	46
Mitochondrial quality control mechanisms as molecular targets in diabetic heart	45
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis	45
Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name	45
UCP1-dependent and UCP1-independent metabolic changes induced by acute cold exposure in brown adipose tissue of mice	45
METTL3 is required for maintaining β-cell function	44
Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic	44
The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the Global Burden of Disease 2000–2019	44
Transition of acute kidney injury to chronic kidney disease: role of metabolic reprogramming	44
Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy	44
Mitochondrial dysfunction in diabetic tubulopathy	43
Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus	42
Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios	41
Advances in biological therapies for dyslipidemias and atherosclerosis	41
Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease	41
Lipids activate skeletal muscle mitochondrial fission and quality control networks to induce insulin resistance in humans	40
Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice	40
Letter to the Editor: Mental Health and Psychological Distress in People with Diabetes during COVID-19	40

Beclin1 haploinsufficiency rescues low ambient temperature-induced cardiac remodeling and contractile dysfunction through inhibition of ferroptosis and mitochondrial injury	40
Regulation of NAD+ metabolism in aging and disease	39
Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts	38
Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone	38
Muscle area and density and risk of all-cause mortality: The Multi-Ethnic Study of Atherosclerosis	37
Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease	37
Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway	36
Pharmacotherapy of type 2 diabetes: An update and future directions	36
Functions of amyloid precursor protein in metabolic diseases	36
Established and emerging factors affecting the progression of nonalcoholic fatty liver disease	36
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors	35
Targeting mammalian serine/threonine-protein kinase 4 through Yes-associated protein/TEA domain transcription factor-mediated epithelial-mesenchymal transition ameliorates diabetic nephropathy orchest	35
Metabolic dysfunction–associated fatty liver disease and the risk of 24 specific cancers	35
Deacetylation of Caveolin-1 by Sirt6 induces autophagy and retards high glucose-stimulated LDL transcytosis and atherosclerosis formation	34
C C chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice	34
Letter to the editor: Unexpected high mortality in COVID-19 and diabetic ketoacidosis	34
The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study	33
Diabetes, glycaemic control, and risk of COVID-19 hospitalisation: Population-based, prospective cohort study	33
SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1	33
Machine learning and semi-targeted lipidomics identify distinct serum lipid signatures in hospitalized COVID-19-positive and COVID-19-negative patients	32
Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists	32
FNDC4, a novel adipokine that reduces lipogenesis and promotes fat browning in human visceral adipocytes	31
Type VI collagen and its cleavage product, endotrophin, cooperatively regulate the adipogenic and lipolytic capacity of adipocytes	31
Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study	31
Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study	31
Exosomes: Advances, development and potential therapeutic strategies in diabetic nephropathy	31
Cholesterol induced autophagy via IRE1/JNK pathway promotes autophagic cell death in heart tissue	30
Basal weekly insulins: the way of the future!	30
Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk	30
Disrupted endothelial cell heterogeneity and network organization impair vascular function in prediabetic obesity	30
Epigenetic modifications in diabetes	29
Hrd1-mediated ACLY ubiquitination alleviate NAFLD in db/db mice	29
Post-transplant obesity impacts long-term survival after liver transplantation	29
CT-derived abdominal adiposity: Distributions and better predictive ability than BMI in a nationwide study of 59,429 adults in China	29
PINK1–PRKN mitophagy suppression by mangiferin promotes a brown-fat-phenotype via PKA-p38 MAPK signalling in murine C3H10T1/2 mesenchymal stem cells	28
Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)	28
11β-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-a systematic review and narrative synthesis	28
Commentary: COVID-19 and obesity pandemics converge into a syndemic requiring urgent and multidisciplinary action	27
A multi-omic analysis of birthweight in newborn cord blood reveals new underlying mechanisms related to cholesterol metabolism	27
Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease	27
Diabetes and metabolic dysfunction-associated fatty liver disease	26
Commentary. Eliminating vitamin D deficiency during the COVID-19 pandemic: A call to action	26
Body fatness associations with cancer: evidence from recent epidemiological studies and future directions	26
Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure	26
The impact of hyperglycaemia on PKM2-mediated NLRP3 inflammasome/stress granule signalling in macrophages and its correlation with plaque vulnerability: an in vivo and in vitro study	26
The role of serum adipokine levels in preeclampsia: A systematic review	26
Bone morphogenetic proteins (BMPs) in the central regulation of energy balance and adult neural plasticity	26
Dietary carbohydrate intake and new-onset diabetes: A nationwide cohort study in China	26
Exercise timing influences multi-tissue metabolome and skeletal muscle proteome profiles in type 2 diabetic patients – A randomized crossover trial	25
Excess body weight is an independent risk factor for severe forms of COVID-19	25
Hepatic insulin-degrading enzyme regulates glucose and insulin homeostasis in diet-induced obese mice	25
Perturbation of the circadian clock and pathogenesis of NAFLD	25
Preparing for the NASH epidemic: A call to action	25
Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?	25
Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors	24
CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status	24
TBC1D15-Drp1 interaction-mediated mitochondrial homeostasis confers cardioprotection against myocardial ischemia/reperfusion injury	24
Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males	23
Higd1a facilitates exercise-mediated alleviation of fatty liver in diet-induced obese mice	23
The IL-8-CXCR1/2 axis contributes to diabetic kidney disease	23
Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes	23
Letter to the Editor: Obesity hypoventilation syndrome and severe COVID-19	23
SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study	23
The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis	23
Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-19	23
Letter to the Editor: Importance of metabolic health in the era of COVID-19	22
Synergistic effects of fructose and glucose on lipoprotein risk factors for cardiovascular disease in young adults	22
Metabolic impact of weight loss induced reduction of adipose ACE-2 – Potential implication in COVID-19 infections?	22
Ubiquitination of PPAR-gamma by pVHL inhibits ACLY expression and lipid metabolism, is implicated in tumor progression	22
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease	22
Hyperglycemia-reduced NAD+ biosynthesis impairs corneal epithelial wound healing in diabetic mice	21
Early adaptive thermogenesis is a determinant of weight loss after six weeks of caloric restriction in overweight subjects	21
Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease	21
Decreased microRNA-125b-5p disrupts follicle steroidogenesis through targeting PAK3/ERK1/2 signalling in mouse preantral follicles	21
ApoCIII: A multifaceted protein in cardiometabolic disease	21
commentary: COVID-19 and Obesity: Exploring Biologic Vulnerabilities, Structural Disparities, and Weight Stigma	21
Maternal high-fat high-sucrose diet and gestational exercise modulate hepatic fat accumulation and liver mitochondrial respiratory capacity in mothers and male offspring	21
Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease	21
Sarcopenia, osteoporosis and frailty	21
The MafA-target gene PPP1R1A regulates GLP1R-mediated amplification of glucose-stimulated insulin secretion in β-cells	21

Vascular smooth muscle cell c-Fos is critical for foam cell formation and atherosclerosis	20
cAMP-response element binding protein mediates podocyte injury in diabetic nephropathy by targeting lncRNA DLX6-AS1	20
Tricarboxylic acid cycle related-metabolites and risk of atrial fibrillation and heart failure	20
SGLT-2 inhibitors as cardio-renal protective agents	20
Management of diabetic neuropathy	20
Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes	20
Artificial intelligence and diabetes technology: A review	19
The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes	19
The effect of dietary patterns on non-alcoholic fatty liver disease diagnosed by biopsy or magnetic resonance in adults: a systematic review of randomised controlled trials	19
Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea	19
Sustained mitochondrial biogenesis is essential to maintain caloric restriction-induced beige adipocytes	19
Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model	19
Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease	19
Incretin-based therapies in 2021 – Current status and perspectives for the future	19
Risk of incident diabetes after COVID-19 infection: A systematic review and meta-analysis	19
Editorial: Obesity, metabolic phenotypes and COVID-19	19
Extra-skeletal effects of bisphosphonates	19
High-density lipoprotein characteristics and coronary artery disease: a Mendelian randomization study	19
Glucose transporter 3 in neuronal glucose metabolism: Health and diseases	19
Association of fatty liver index with all-cause and disease-specific mortality: A nationwide cohort study	19
Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe di	19
Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD	19
Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy	18
Identification of a novel leptin receptor (LEPR) variant and proof of functional relevance directing treatment decisions in patients with morbid obesity	18
Loss of postprandial insulin clearance control by Insulin-degrading enzyme drives dysmetabolism traits	18
AMP deamination is sufficient to replicate an atrophy-like metabolic phenotype in skeletal muscle	18
Deletion of BCATm increases insulin-stimulated glucose oxidation in the heart	18
Pharmacological activation of REV-ERBα improves nonalcoholic steatohepatitis by regulating intestinal permeability	18
Apolipoprotein C3 aggravates diabetic nephropathy in type 1 diabetes by activating the renal TLR2/NF-κB pathway	18
Association of class number, cumulative exposure, and earlier initiation of antibiotics during the first two-years of life with subsequent childhood obesity	18
Diabetic ketoacidosis in pediatric patients with type 1- and type 2 diabetes during the COVID-19 pandemic	18
Loss of iRhom2 accelerates fat gain and insulin resistance in diet-induced obesity despite reduced adipose tissue inflammation	18
GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease	18
Recent advances in closed-loop insulin delivery	17
Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies	17
Adiponectin promotes repair of renal tubular epithelial cells by regulating mitochondrial biogenesis and function	17
Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?	17
TMBIM6 prevents VDAC1 multimerization and improves mitochondrial quality control to reduce sepsis-related myocardial injury	17
Beyond mitochondria: Alternative energy-producing pathways from all strata of life	17
ApoC2 deficiency elicits severe hypertriglyceridemia and spontaneous atherosclerosis: A rodent model rescued from neonatal death	17
Altered metabolic and hormonal responses to moderate exercise in overweight/obesity	17
Mendelian randomization study of obesity and type 2 diabetes in hospitalized COVID-19 patients	17
Inhibition of miR-153, an IL-1β-responsive miRNA, prevents beta cell failure and inflammation-associated diabetes	17
Increased AMP deaminase activity decreases ATP content and slows protein degradation in cultured skeletal muscle	17
Adiponectin's mechanisms in high-density lipoprotein biogenesis and cholesterol efflux	17
Histone methyltransferases G9a mediated lipid-induced M1 macrophage polarization through negatively regulating CD36	17
AMP-activated protein kinase (AMPK) signaling in GnRH neurons links energy status and reproduction	16
FGF21 and Chronic Kidney Disease	16
Circulating α-klotho regulates metabolism via distinct central and peripheral mechanisms	16
Effects of aerobic exercise on fibroblast growth factor 21 in overweight and obesity. A systematic review	16
From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need	16
The β-cell glucose toxicity hypothesis: Attractive but difficult to prove	16
Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis	16
Brown adipose tissue transplantation ameliorates diabetic nephropathy through the miR-30b pathway by targeting Runx1	16
Systematic review with meta-analysis of diagnostic test accuracy for COVID-19 by mass spectrometry	16
miRNA-22 deletion limits white adipose expansion and activates brown fat to attenuate high-fat diet-induced fat mass accumulation	15
Dissecting causal relationships between nonalcoholic fatty liver disease proxied by chronically elevated alanine transaminase levels and 34 extrahepatic diseases	15
Sarcopenia in youth	15
Adipose tissue adipokines and lipokines: Functions and regulatory mechanism in skeletal muscle development and homeostasis	15
Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study	15
Metformin-induced TTP mediates communication between Kupffer cells and hepatocytes to alleviate hepatic steatosis by regulating lipophagy and necroptosis	15
Associations of abdominal muscle area and density with coronary artery calcium volume and density: The multi-ethnic study of atherosclerosis	15
YY1 deficiency in β-cells leads to mitochondrial dysfunction and diabetes in mice	15
Letter to the Editor: Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes: what this means for an effective management strategy	15
SLC46A1 contributes to hepatic iron metabolism by importing heme in hepatocytes	14
Laminins in metabolic tissues	14
The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling	14
Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?	14
Defects in High Density Lipoprotein metabolism and hepatic steatosis in mice with liver-specific ablation of Hepatocyte Nuclear Factor 4A	14
Inhibiting glycolysis rescues memory impairment in an intellectual disability Gdi1-null mouse	14
Taurine treatment reverses protein malnutrition-induced endothelial dysfunction of the pancreatic vasculature: The role of hydrogen sulfide	14
Downregulation of NK cell activities in Apolipoprotein C-III-induced hyperlipidemia resulting from lipid-induced metabolic reprogramming and crosstalk with lipid-laden dendritic cells	14
Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist	14
AGEs exacerbates coronary microvascular dysfunction in NoCAD by activating endoplasmic reticulum stress-mediated PERK signaling pathway	14
Effects of bariatric surgery on lipid-lipoprotein profile	14
Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters	14
Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort	14
PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study	14
Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives	14
A requirement for PAK1 to support mitochondrial function and maintain cellular redox balance via electron transport chain proteins to prevent β-cell apoptosis	14
Urinary GC–MS steroid metabotyping in treated children with congenital adrenal hyperplasia.	14
Role of apolipoprotein E in electronegative low-density lipoprotein-induced mitochondrial dysfunction in cardiomyocytes	13
Elevated FURIN levels in predicting mortality and cardiovascular events in patients with acute myocardial infarction	13
Sarcopenic obesity: emerging mechanisms and therapeutic potential	13
Noradrenergic fibers are associated with beta-cell dedifferentiation and impaired beta-cell function in humans	13
The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes	13
Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)	13
Adherence to the EAT-Lancet diet, genetic susceptibility, and risk of type 2 diabetes in Swedish adults	13
Prandial hepatic glucose production during hypoglycemia is altered after gastric bypass surgery and sleeve gastrectomy	13
Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation	13
Absence of AGPAT2 impairs brown adipogenesis, increases IFN stimulated gene expression and alters mitochondrial morphology	13
Current and investigational medications for the treatment of sarcopenia	13
Endothelial sodium channel activation promotes cardiac stiffness and diastolic dysfunction in Western diet fed female mice	13
MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice	13
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity	13